ZL-1310

ZL-1310 is an antibody-drug conjugate developed by Zai Lab (Shanghai). Its target is DLL3 (the sponsor names DLL3). The sponsor states: ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)), in non-small-cell lung cancer. The largest, NCT07218146, plans to enrol 480 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.